ReviewPathogens (Basel, Switzerland)2022
Adaptive Cellular Immunity against African Swine Fever Virus Infections.
Review in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 84 citations in OpenAlex.
- A dual-gene-deleted ASFV Lv17/WB/Rie1-ΔCD candidate administered orally to wild boar confers DIVA-compatible protection against virulent challenge.The veterinary quarterly · 2026Article
- Limited cross-protection induced by live attenuated ASF vaccines emphasizes caution for field use.Emerging microbes & infections · 2026Article
- Correlates of protection against African swine fever virus identified by a systems immunology approach.eLife · 2026Article
- Virus-like and Virus Replicon Particles Targeting Multiple B-Cell Antigens Do Not Protect Against African Swine Fever Virus.Vaccines · 2026Article
- Duration of immunity following infection with moderately virulent ASFV.PLoS pathogens · 2026Article
- Article
- Live-vectored antigen cocktail confers protection against African swine fever virus (ASFV) Georgia 2007/1 challenge.NPJ vaccines · 2026Article
- How the wild things are: comparative T cell phenotyping and memory T cell identification in wild boar and domestic pigs.Frontiers in immunology · 2026Article
- Dynamics of leukocyte populations, immune-regulatory cytokines, and biochemical parameters in wild boar and domestic pigs experimentally infected with a virulent African swine fever virus genotype II strain.Frontiers in immunology · 2026Article
- Implications for safety:Frontiers in microbiology · 2026Article
- Identification and efficacy assessment of novel immunoprotective antigens from Mycoplasma synoviae for vaccine development.NPJ vaccines · 2025Article
- Breed Varieties of Pigs for Disease Resistance and Susceptibility to Seneca Valley Virus Infection.International journal of molecular sciences · 2025Article
- Single-Cell Atlas of Spleen Remodeling Reveals Macrophage Subset-Driven ASFV Pathogenesis.Biology · 2025Article
- Development and efficacy of a novel mRNA cocktail for the delivery of African swine fever virus antigens and induction of immune responses.Microbiology spectrum · 2025Article
- African swine fever virus: Virology, pathogenesis, clinical impact, and global control strategies.Veterinary world · 2025Review
- Designing a multi-epitope vaccine against African swine fever virus using immunoinformatics approach.Scientific reports · 2025Article
- Design of a Multiepitope Pan-Proteomic mRNA Vaccine Construct Against African Swine Fever Virus: A Reverse Vaccinology Approach.Veterinary medicine international · 2025Article
- Pathogenicity and virulence of African swine fever virus.Virulence · 2024Review
- Review
- Advancement in the Antigenic Epitopes and Vaccine Adjuvants of African Swine Fever Virus.Pathogens (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
African swine fever virus (ASFV) remains a threat to global pig populations. Infections with ASFV lead to a hemorrhagic disease with up to 100% lethality in Eurasian domestic and wild pigs. Although myeloid cells are the main target cells for ASFV, T cell responses are impacted by the infection as well. The complex responses remain not well understood, and, consequently, there is no commercially available vaccine. Here, we review the current knowledge about the induction of antiviral T cell responses by cells of the myeloid lineage, as well as T cell responses in infected animals, recent efforts in vaccine research, and T cell epitopes present in ASFV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.